CytoSorbents Corporation (CTSO) オプション

Texas banned abortion. Then sepsis rates soared.

By Lizzie Presser, Andrea Suozzo, Sophie Chou and Kavitha Surana, ProPublica 11 minute read
Published 7:00 AM EST, Fri February 21, 2025

This story was originally published by ProPublica.
?ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive its biggest stories as soon as they’re published.

Pregnancy became far more dangerous in Texas after the state banned abortion in 2021, ProPublica found in a first-of-its-kind data analysis.

The rate of sepsis shot up more than 50% for women hospitalized when they lost their pregnancies in the second trimester, ProPublica found.

The surge in this life-threatening condition, caused by infection, was most pronounced for patients whose fetus may still have had a heartbeat when they arrived at the hospital.


ProPublica previously reported on two such cases in which miscarrying women in Texas died of sepsis after doctors delayed evacuating their uteruses. Doing so would have been considered an abortion.

The new reporting shows that, after the state banned abortion, dozens more pregnant and postpartum women died in Texas hospitals than had in pre-pandemic years, which ProPublica used as a baseline to avoid COVID-19-related distortions. As the maternal mortality rate dropped nationally, ProPublica found, it rose substantially in Texas.

ProPublica’s analysis is the most detailed look yet at a rise in life-threatening complications for women losing a pregnancy after Texas banned abortion. It raises concerns that the same pattern may be occurring in more than a dozen other states with similar bans.

To chart the scope of pregnancy-related infections, ProPublica purchased and analyzed seven years of Texas’ hospital discharge data.



https://www.cnn.com/2025/02/21/health/texas-sepsis-abortion-propublica/index.html

PubMed From 2022...

Antithrombotic drug removal from whole blood using Haemoadsorption with a porous polymer bead sorbent
Ritu Tripathi et al. Eur Heart J Cardiovasc Pharmacother. 2022.

Abstract
Aim: To evaluate the ability of the DrugSorb™-AntiThrombotic Removal (ATR) haemoadsorption device utilizing porous polymer bead sorbent technology to remove three commonly used antithrombotic drugs from whole blood.

Methods and results: We evaluated the removal of apixaban, rivaroxaban, and ticagrelor by the DrugSorb-ATR haemoadsorption device in a benchtop clinical scale model using bovine whole blood. Blood spiked at clinically relevant concentrations of an antithrombotic agent was continuously circulated through a 300-mL DrugSorb-ATR haemoadsorption device at a flow rate of 300 mL/min. Drug concentration was monitored over 6 h to evaluate drug removal. Results were compared with a control circuit without the haemoadsorption device. Removal rates at 30, 60, 120, and 360 minutes were: apixaban: 81.5%, 96.3%, 99.3% >99.8%; rivaroxaban: 80.7%, 95.1%, 98.9%, >99.5%; ticagrelor: 62.5%; 75%, 86.6%, >95% (all P

SEC filing of a 13G was all I could locate from yesterday. Volume almost 3x !

Volume 2/14/2025 - 737,237 Shares

It got really crazy on Level II late in the afternoon yesterday. Avenir has held a large position of CTSO for some time and I'm very sure this couldn't have been the culprit of yesterday's trading. Somebody must have jumped the gun and triggered fomo mayhem imo.

Name of person filing:
AVENIR CORP

Signature: James H. Rooney
Name/Title: President
Date: 02/14/2025

Amount beneficially owned:
3,093,946

This Schedule 13G ("Schedule") is being filed on behalf of Avenir
Corporation ("Avenir"), a Virginia corporation, and James H.
Rooney (Mr. Rooney along with Avenir are "Reporting Persons").

Avenir is an investment adviser registered under the Investment Advisers Act of
1940, as amended ("Advisers Act").
Mr. Rooney is the portfolio manager and a shareholder of Avenir.
Percent of class represented by amount in row (9)
5.7 %

https://www.sec.gov/Archives/edgar/data/1033475/000103347525000004/xslSCHEDULE_13G_X01/primary_doc.xml

FDA News out???

After 7 years of declining performance and giving shareholders nothing for $4O million in government grants ( which they ran though income statement as revenues) this incompetent CEO still overstates their opportunities . The really BIG GLOBAL opportunity is IMHO the HemoDefend product for blood purification that every blood bank, ambulance , cruise ship , submarine and naval vessel would carry. $20 million in DOD grants so far and zilch! . Freeze dried version could be a $500 million annual revenue business with over 70% gross margins in a few years. A great opportunity for whoever owns this company in 2026.

CytoSorbents

#PuriFi successfully put into operation at Cardiacsurgery Department, KBC Hospital Split, Croatia

"We are proud to announce the successful installation of the PuriFi standalone machine at the Cardiacsurgery Department at KBC Hospital Split, Croatia. Known for their pioneering approach, the team at KBC Split continues to lead the way in adopting cutting-edge medical technologies.
With this standalone configuration, you can use CytoSorb Therapy whenever and wherever your patients need its proven benefits."
Find out more and get in touch with our team at https://cytosorbents.com/purifi/
#CytoSorb #InnovationInHealthcare #Hemoadsorption #MedicalTechnology KBC Split

Revolutionizing Severe Malaria Management: The Role of CytoSorb® Hemoadsorption in Treating Malaria-Induced Liver Dysfunction

Rosanna Carmela De Rosa • Antonio Romanelli • Roberto Giurazza • Fabrizio Falso • Gianfranco Viola

Published: January 20, 2025

Conclusions
In conclusion, the use of the EHA is safe and effective in achieving a favorable outcome for patients with PF malaria waiting for the effect of antimalarial therapy. The bilirubin removal by CytoSorb® hemofilter allowed us to create a "bridge" for specific therapy, improve symptoms, and prevent organ damage. This case supports further exploration of the use of EHA with CytoSorb® in managing severe malaria cases. Specific areas of research could include evaluating its impact on inflammatory markers, bilirubin clearance, and organ function recovery in patients with malaria-induced multiorgan dysfunction. Additionally, studies should investigate optimal timing, duration of therapy, and patient selection criteria to maximize the benefits.

https://www.cureus.com/articles/327010-revolutionizing-severe-malaria-management-the-role-of-cytosorb-hemoadsorption-in-treating-malaria-induced-liver-dysfunction#!/

Why not more recent light given to other products as well such as VetResQ?

CytoSorbents Press Release
CytoSorbents Launches VetResQ™ for U.S. Veterinary Market

VetResQ Adds Advanced, First-In-Kind Blood Purification Treatment of Inflammatory Toxins to the U.S. Veterinary Market. Debuts at American College of Veterinary Emergency and Critical Care Post-Graduate Review Conference.

MONMOUTH JUNCTION, N.J., Jan. 20, 2017 /PRNewswire/ --

"CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using blood purification to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces the marketing launch and commercial availability of the VetResQ™ sorbent cartridge for the United States veterinary market. VetResQ is a broad spectrum blood purification adsorber designed to help treat deadly inflammation and toxic injury in animals with critical illnesses such as septic shock, toxic shock syndrome, severe systemic inflammation, toxin-mediated diseases, pancreatitis, trauma, liver failure, and drug intoxication."

We should be good here. I'm not selling. Universal Plasma next on the list.

Agreed!
I wasn’t sure how the rights offering would pan out. Now I know. Cytosorbents bought themselves another year of cash flow which should be enough time for the FDA “nod”. I’m optimistic that they will get the approval, and that analyst Jason Kolbert $10 price target is attainable. 🙂
Getting a little nostalgic but maybe even getting back into the lower teens like 2019.
Have a great investing day!!

We need the FDA "nod" or it won't matter !

The Rights Offering was oversubscribed by 68% with total demand of 10,514,896 Units, including the exercise of both basic subscription rights and oversubscriptions.

CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai

Mon, January 6, 2025 at 7:00 AM EST 6 min read

PRINCETON, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the opening of a new regional sales subsidiary in Dubai, United Arab Emirates (UAE). The new subsidiary provides a gateway into the Middle East and Africa - regions with increasing demand for advanced medical technologies and high-quality therapies in critical care and cardiac surgery.

“Establishing a central commercial presence in Dubai represents a major milestone in our regional expansion strategy, reflecting our commitment to accelerating sales growth in this critical international market," said Dr. Phillip Chan, Chief Executive Officer of CytoSorbents. “Our business in the region has been growing over the past several years, and this new subsidiary is expected to be a key international sales center that will help us strengthen and better support existing partnerships, foster closer on-the-ground interactions with customers to augment sales, forge new alliances, and drive long-term value creation.”

CytoSorbents has established its new commercial office in the heart of Dubai’s Science Park, a commercial, healthcare-focused, “free zone” with special economic benefits, that will serve as a hub for regional sales and business development, training, customer support, and regulatory affairs. The UAE is the regional home of many multinational medical device companies and was selected because of its strategic location, strong economy and favorable tax policies, advanced infrastructure, well-developed healthcare system, and supportive economic and regulatory policies.

Dr. Chan continued, “The Middle East and Africa continue to experience rapid growth in the demand for cutting-edge healthcare technologies such as CytoSorb® and we are thrilled to be at the forefront of this transformation. We look forward to working closely with healthcare providers, regulators, and key stakeholders to establish CytoSorbents as a leader in critical care and cardiac surgery across this dynamic region.”

https://finance.yahoo.com/news/cytosorbents-expands-global-footprint-opening-120000074.html

Wow ! Premarket Shank... Somebody left the toilet seat up, jumped the gun and bought premarket on pr qtr news release and got burned by buying way over a buck early this morning. Hundreds of thousands of shares. Yikes! A real arse serving 🤣

I believe in Santa Claus, but I don't belive you will see .65. It has never been that low, and now it is near FDA approval and will zoom.

Just wait for .65 & F the share rights offering.

View all Cytosorbents Medical Inc reviews
1.0

Sub-Zero Morale
Former Employee (Former Employee) - Princeton, NJ - August 12, 2024
This is a place that you should only consider in desperation, morale is at sub-zero levels. There are no perks, no bonus, there are only upsidedown stock option offerings. Everyone is asked to wear too many "hats" due to the extremely high turnover rate. It is really unsettling to see your coworkers just disappearing due to the turnover and surprise layoffs.

How many employees are they down to now?

if you read more, you would see that you get one share of the company PLUS the opportunity to purchase furture shares at at lower than market price. That is, if the share price increases.

Shorts aren't gonna let them raise money. WOW ! 😄

& Falling .82 now.

.85 HORRIBLE !!!

Am I missing something or was Tattoo's LATEST FAILURE be offering shares to investors for $1? They are currently trading well below a buck at the market so why would anyone be stupid enough to buy them for a buck?

"The Filter, The Filter...!!!"

Must be traders taking losses for the year against gains.

Cytosorbents CFO Peter Mariani buys $27,974 in stock
Investing.com
Published 12/13/2024, 08:01 AM


These open market purchases reflect Mariani's ongoing investment in the company, increasing his total holdings to 381,363 shares. With analyst price targets ranging from $1 to $10, investors seeking deeper insights can access comprehensive analysis and additional ProTips through InvestingPro's detailed research reports. With analyst price targets ranging from $1 to $10, investors seeking deeper insights can access comprehensive analysis and additional ProTips through InvestingPro's detailed research reports. These open market purchases reflect Mariani's ongoing investment in the company, increasing his total holdings to 381,363 shares.

In other recent news, CytoSorbents Corporation has announced the terms of an upcoming Rights Offering. The medical technology company aims to raise between $3.0 million and $5.0 million through the offering, which is expected to significantly improve liquidity. The proceeds are intended for general corporate purposes and to support operations through anticipated regulatory decisions on the company's DrugSorb-ATR marketing applications in 2025.

Simultaneously, CytoSorbents reported an 11% year-over-year increase in product sales for the third quarter of 2024, totaling $8.6 million. The company's flagship product, CytoSorb, has generated approximately $34 million in sales over the past year. Additionally, the company has made progress in its blood purification technology, particularly for critical care and cardiac surgery applications.

CytoSorbents is also preparing for the launch of DrugSorb ATR, a device aimed at reducing perioperative bleeding. The device has received two FDA breakthrough designations and is awaiting regulatory decisions from the FDA and Health Canada, expected in 2025. Amid these developments, CytoSorbents has managed to decrease its operating expenses by 25% and reduce its cash burn to $2.7 million.

https://www.investing.com/news/insider-trading-news/cytosorbents-cfo-peter-mariani-buys-27974-in-stock-93CH-3771413

That guy is on every cc and he (most of the time in the past) gets a question in at the end of each call. He hasn't hit or even come close to his target (below or above) in over a decade plus !

Longtime supporter now lead less so-/
Cytosorbents Co. (NASDAQ:CTSO – Free Report) – Stock analysts at HC Wainwright dropped their FY2024 earnings estimates for shares of Cytosorbents in a research note issued on Monday, November 11th. HC Wainwright analyst S. Lee now expects that the medical research company will post earnings of ($0.30) per share for the year, down from their prior forecast of ($0.29). HC Wainwright has a “Neutral” rating and a $1.00 price objective on the stock.

India deal announced. How much cash might they be paying/investing ?

EF Hutton says:
https://efhuttongroup.bluematrix.com/links2/pdf/0f38ff9c-e219-4baf-ba37-56242bb40ecb
Huge outlier analyst….

Is EF Hutton like SCR Zacks paid by company to write research?

“Already approved “ ? How would you know that’s??? No way. “time will tell”
Do not expect this team to suddenly behind better managers after horrible record. An important tell tale sign that longtime CFO left!!!!

We might not be impacted by new FDA medical device "boss". I think our approval for this MUCH needed problem is already approved and in the books. Probably just needs the i's doted and the t's crossed before approval. We'll have to wait and see.

A new FDA boss might not be good for CTSO and their tight schedule before they run out of cash.
https://www.nytimes.com/2024/10/22/health/fda-medical-devices.html?smid=nytcore-ios-share&referringSource=articleShare

Excerpts from EF Hutton Oct 1 report:
"Was the Trial a Failure or a Success? The initial data analysis showed that the
primary effectiveness endpoint in the overall patient population that underwent
different cardiac surgeries was unmet. However, the pre-specified subpopulation of
patients undergoing isolated coronary artery bypass graft (CABG) surgery, which
accounted for 90% of patients enrolled in the trial, showed evidence of reduced
bleeding complications, including serious bleeding events"

Also disclosed new info about manufacturing problem:
. "A planned slowdown in production to rebalance inventory, combined with a shortterm manufacturing issue, led to fewer CytoSorb devices produced and lower product gross margins of 50% to 60%, down from 71% in Q3 2023"
Has Management disclosed this to shareholders????

Reposted from Stocktwiitts-Zack’s report from last week:
https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_10012024_CTSO_Kerr.pdf

Ranch, nice job with hemo plasma post. Thanks for going the extra and adding much needed substance here.

Under the Freedom of Information Act one can retrieve some of the DOD filings of progress under CTSO Award W81XWH-22-C-0046.
In a recent April 2024 filing statement by Dr. Maryann Gruda she stated:
"Greater availablilty of universal plasma products wil significantly simplfy logistics and reduce costs for both military and civilian transfusion services. Phase II SBIR studies perfomred at WRNMMC showed the BGA-Absorber prototype removed anti-A-titer and anti-B titers by 99% from high titer human plasma, without affecting coagulation factors. Building on these exciting results, our proposed efforts are directed towards combining BGA reduction with spray or freeze-drying efforts to generate universal dried plasma that is suitable and readily available under austere conditions".
The May filing actually shows how the product packaging would work.

In many ways this opporunity seems much lager, more profitable and sooner benefit to shareholders than current FDA approvals underway.
Why is Dr. Chan not talking about this?
Maybe to some investors looking at the new Jefferies $20 million raise?
Looking forward to additional filings.
Maybe a major medical device company like Boston Scientfic or Medtronic could swoop in, buy CTSO under an unfriedly tender for $60-80 milion, fire the Board and all the overhead people, keep the new manufacturing facility and use their own global distribution to quickly build a $200-500 million annual business (with 75% plus gross margins) selling to every naval ship, cruise ship, amubulance, EMS, police and fire fleet?

NEWS -- CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update



The De Novo medical device application for DrugSorb™-ATR is eligible for FDA priority review as an FDA Breakthrough Designated Device for this indicationThe Health Canada Medical Device License application is ready for submission, pending the expected receipt of Medical Device Single Audit Program (MDSAP) certification in the near futureExpecting FDA and Health Canada decisions in 2025PRINCETON, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces the submission of its DrugSorb™-ATR medical device De Novo marketing application to the U.S. Food and Drug Administration (FDA) on September 27, 2024, to reduce the severity of perioperative bleeding in patients on ticagrelor (Brilinta®, AstraZeneca) undergoing coronary artery bypass graft (CABG) surgery. The FDA has previously granted Breakthrough Device Designation to DrugSorb-ATR to address this major unmet medical need, making it eligible for priority review.

“The DrugSorb-ATR De Novo submission to FDA is the culmination of multiple years of significant clinical, regulatory, and manufacturing accomplishments company-wide, centered on the execution and data analysis from the U.S. and Canadian pivotal STAR-T randomized controlled trial and the product development of DrugSorb-ATR,” stated Dr. Phillip Chan, Chief Executive Officer of CytoSorbents. “We are very proud of our dedicated CytoSorbents team and external clinicians, collaborators, and consultants who helped to achieve this major milestone. We look forward to interactions with FDA and the timely review of our application. Meanwhile, we have also completed our DrugSorb-ATR Health Canada Medical Device License (MDL) application, which will be submitted with the expected near-term receipt of MDSAP certification.”

Ticagrelor is a blood thinning drug frequently administered in the hospital to patients suffering from a heart attack. If patients are not eligible for a coronary stent, they will often require CABG surgery to restore blood flow to heart muscle. Current guidelines recommend the delay of surgery by three to five days to allow “washout” or natural elimination of the drug to reduce the high risk of serious and potentially fatal perioperative bleeding from the use of the blood thinner. The 140-patient North American pivotal STAR-T randomized, double-blind, sham-controlled trial evaluated the safety and efficacy of DrugSorb-ATR in patients undergoing urgent CABG surgery on ticagrelor to remove the drug and reduce the severity of perioperative bleeding complications compared with patients operated without the device. These safety and efficacy data from STAR-T form the basis of our marketing approval submissions.

About the U.S. and Canadian Regulatory Pathways

The U.S. FDA De Novo process for medical devices provides a marketing pathway to classify novel medical devices for which general controls alone, or general and special controls, provide reasonable assurance of safety and effectiveness for the intended use, but for which there is no legally marketed predicate device. Following application acceptance by FDA, De Novo submissions enter the substantive review phase where FDA Breakthrough Device designation and an associated interactive priority review, called “sprint discussions,” can accelerate the process.

The Health Canada Medical Device License (MDL) authorizes manufacturers to import or sell Class II, III, and IV medical devices in Canada. The license ensures that these devices meet the necessary safety, quality, and efficacy standards as per the Medical Devices Regulations. MDL requires MDSAP certification, which the Company expects to receive shortly, at which point it will file its MDL application.

Final regulatory decisions on DrugSorb-ATR are expected from FDA and Health Canada in 2025. DrugSorb-ATR is not yet approved or cleared in the U.S. or Canada.

Preliminary, Selected Third Quarter 2024 Financial Results and Business Update

We estimate that our Q3 2024 Product Sales (excluding grant income) will be in the range of approximately $8.3 million to $8.5 million, representing growth of 7% to 10%, versus $7.8 million in Q3 2023.A planned temporary slowdown in production to rebalance inventory levels coupled with a short-term manufacturing issue resulted in a significantly lower number of CytoSorb devices produced in the quarter. Because of this, we estimate that our product gross margins for Q3 2024 will be in the range of approximately 50% - 60%, compared to 71% in Q3 2023. The Company believes the short-term manufacturing issue has been resolved and expects a return to more normalized production levels and product gross margins in Q4 2024. The Company continues to have sufficient inventory to meet demand.About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents’ proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, ECMO, heart-lung machines). CytoSorbents’ technologies are used in a number of broad applications. Two important ones are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding and 2) the removal of inflammatory agents in common critical illnesses such as sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.

CytoSorbents’ lead product, CytoSorb®, is approved in the European Union and distributed in 76 countries worldwide, with more than 250,000 devices used cumulatively to date. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. CytoSorb is not yet approved or cleared in the United States.

In the U.S. and Canada, CytoSorbents is developing the DrugSorb™-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two FDA Breakthrough Device Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures. In September 2024, the Company submitted a De Novo medical device application to the U.S. FDA requesting marketing approval to remove ticagrelor and reduce the severity of perioperative bleeding in CABG patients on the drug. The Company expects to submit its completed Health Canada Medical Device License (MDL) application, pending the expected receipt of Medical Device Single Audit Program (MDSAP) certification in the near future. DrugSorb-ATR is not yet approved or cleared in the United States and Canada.

The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, ContrastSorb, and others. For more information, please visit the Company’s website at https://www.cytosorbents.com or follow us on Facebook and X.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 14, 2024, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Please Click to Follow Us on Facebook and X

U.S. Company Contact:
Peter J. Mariani, Chief Financial Officer
305 College Road East
Princeton, NJ 08540
mailto://pmariani@cytosorbents.com

Investor Relations Contact:
Aman Patel, CFA
Investor Relations, ICR-Westwicke
(443) 450-4191
mailto://ir@cytosorbents.com

Company files $150 million effectiveness prospectus today;
https://www.sec.gov/Archives/edgar/data/1175151/000110465924103199/tm2424757d1_s3a.htm#sp1-001
Delusinal management? This is almost TWICE the total market capitalization of company!

Unfortunately they have not been able to get approval for a broad sepsis treatment. 7-8 years ago they had research grant and hired a research team at University of Pittsburgh. It failed to prove a broad solution so they pivoted to much narrower applications.

Some think Chan and their scientific team made a HUGE blunder in not accelerating their HemoDefend application ( also under $15 million + grants) with Department of Defense to provide a kit to take any blood type , run it through a special cartridge bag, and create a UNIVERSAL blood plasma. A HUGE global market to be carried in every ambulance , EMS vehicles, naval ships, cruise ships etc. could be easily manufactured in their new NJ facility. Easily a $300-400 million global market annually within 2years of introduction with 85% gross margins. DOD wants a freeze dried version which is being worked on. IMHO this product would get FDA approval relatively quickly and would save the company and easily move the stock to $7-10. Chan has tied his fortune and that of the company to a weaker opportunity. CFO has left with handwriting on the wall. A shame.
After they run out of cash whoever acquires CTSO assets and intellectual property on this product line will make a fortune. There are several medical device companies with great balance sheets and superb global marketing/sales forces waiting in the wings to scoop up the carcass Chan will leave in 18 months.

https://wtop.com/health-fitness/2024/09/sepsis-remains-a-relatively-unknown-condition-despite-killing-more-than-300000-americans-every-year/

Phil Chan here at CTSO and Neil Chan at IGEN have both destroyed a tremendous amount of shareholder capital through bad choices and mismanagement. Board a disaster.

You seem the type who buys into every lie told to you by penny stock pump and dumpers. A 3 second look at the financials and your claim and I see short interest small and falling.

Short Interest
Latest
1.39 M
Previous
1.42 M
% Change
-1.72%
% Float Short
2.66%
DTC

Nasdaq coming for them in new purge?
https://www.wsj.com/finance/stocks/nasdaq-penny-stock-proposed-rule-change-74677b00?st=9d6hc8olx75pnon&reflink=article_copyURL_share

Sounds like Kathleen has had enough of this nut show. What a shame.
So just exactly how much $ money does the company actually have today August 13, 2024?

Who do you guess the bonehead exec from CTSO that set that up was ? ;)

A reminder from today's 10K SEC filing:
Pursuant to an agreement dated August 11, 2003, an existing investor agreed to make a $4 million equity investment in the Company. These amounts were received by the Company in 2003. In connection with this agreement the Company granted the investor a perpetual royalty of 3% on all gross revenues received by the Company from the sale of its CytoSorb device which such rights were assigned to an existing investor in 2017. For the three months ended June 30, 2024 and 2023, the Company recorded royalty expenses of approximately $264,000 and $240,000, respectively. For the six months ended June 30, 2024 and 2023, the Company recorded royalty expenses of approximately $531,000 and $474,000, respectively. These expenses are included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss.

EF Hutton initiated a $10 Target yesterday on CTSO. I can let you know the link is inside Schwab "thinkorswim" trading platform under news tab. Shorts are trying to play it down. I smell a short squeeze big time.

https://www.reddit.com/r/Cytosorbents/s/6Hc9OvNeha

NEWS -- CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website



“Working to Save Lives Together” Theme Highlights Two Decades of Successful Collaboration with the International Medical and Research Communities to Help Patients Survive Life-Threatening Illnesses

PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, is proud to announce the launch of its newly redesigned and consolidated website at https://www.cytosorbents.com. The theme of “Working to Save Lives Together” highlights two decades of successful collaboration with the international medical and research communities to continuously refine how our therapies, such as CytoSorb®, ECOS-300CY®, and VetResQ® are being used to help patients survive life-threatening illnesses.

A Modern, Unified Online Presence

The new website, built from the ground up, unifies our corporate and product information into a single, cohesive and comprehensive information hub for healthcare professionals, investors, and other key stakeholders. Visitors will find a streamlined modern design, intuitive navigation, and extensive content on our company, technology, therapies, pipeline that includes DrugSorb™-ATR and HemoDefend-BGA™, clinical studies, investor conferences, and much more.

Key Features of the New Website:

User-Friendly Layout and Intuitive Navigation - with easy access to essential information and optimized for both desktop and mobile browsing.Enhanced Easy-to-Understand Content - tailored for different stakeholders.News and Updates - dedicated to the latest developments and events.Comprehensive and Searchable Resource Library - from a collection of 1,000+ peer-reviewed publications, poster presentations, abstracts, white papers and case reports highlighting the use of our therapies in many applications.Introduction to Our Experts - who are there to provide guidance and support.Voices Around the World - with insights and feedback from users worldwide.Dedicated Investor Relations site - for quick access to investor materials.Improved Contact Forms - facilitating faster communications and interactions.Dr. Christian Steiner, Executive Vice President of Sales and Marketing of CytoSorbents, stated, “We are grateful to all of the pioneering physicians, nurses, perfusionists, researchers, and other healthcare professionals who use our therapies in daily clinical practice or who have contributed to the many studies and the more than 1,000 references that can be found in our CytoSorb literature database on our new website. Your dedication and insights have been instrumental in shaping the success of our technology and improving patient outcomes worldwide. Likewise, as we have in the past, it is our commitment to you to be a trusted and dependable partner who will be there to support you whenever you need us.”

Dr. Steiner added, “We invite everyone to explore the new CytoSorbents website which is a celebration of all that we have accomplished together, and to learn how CytoSorbents is helping to save lives and ‘Expand the Dimension of Blood Purification™’ with our products around the world.”

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification. Its lead product, CytoSorb®, is approved in the European Union and distributed in 75 countries worldwide. It is an extracorporeal cytokine adsorber that reduces “cytokine storm” or “cytokine release syndrome” in common critical illnesses that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorb is also used during and after cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, including severe bleeding and multiple organ failure. As of March 31, 2024, more than 237,000 CytoSorb devices have been used cumulatively. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. CytoSorb is not yet approved in the United States.

The DrugSorb™-ATR antithrombotic removal system, an investigational device based on the same polymer technology as CytoSorb, has received two FDA Breakthrough Device Designations, one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures. The Company has completed the FDA-approved, randomized, controlled STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) study of 140 patients at approximately 30 centers in U.S. and Canada to evaluate whether intraoperative use of DrugSorb-ATR can reduce the perioperative risk of bleeding in patients receiving ticagrelor and undergoing cardiothoracic surgery. This pivotal study is intended to support U.S. FDA and Health Canada marketing approval for DrugSorb-ATR in this application.

CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of approximately $50 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, ContrastSorb, and others. For more information, please visit the Company’s websites at https://www.cytosorbents.com and https://www.cytosorb.com or follow us on Facebook and X.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, statements about potential exposures resulting from our cash positions, representations and contentions, and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 14, 2024, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Please Click to Follow Us on Facebook and X

U.S. Company Contact:
Kathleen Bloch, CFO
305 College Road East
Princeton, NJ 08540
+1 (732) 398-5429
mailto://kbloch@cytosorbents.com

Investor Relations Contact:
Eric Ribner
LifeSci Advisors, LLC
250 W 55th St, #3401
New York, NY 10019
+1 (646) 751-4363
mailto://ir@cytosorbents.com